Optimized Erythropoietin (EPO) Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

June 30, 2019

Study Completion Date

December 31, 2019

Conditions
Neonatal Anemia
Interventions
DRUG

Epoetin Alpha

"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.~Infant study 2:~Dosing algorithm will be determined by results of Infant Study 1."

DRUG

Biotinylated Red Blood Cells

Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.

Trial Locations (1)

52242

University of Iowa Hospitals and Clinics, Iowa City

All Listed Sponsors
collaborator

Department of Health and Human Services

FED

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

Janssen Scientific Affairs, LLC

INDUSTRY

lead

John A Widness

OTHER

NCT02075970 - Optimized Erythropoietin (EPO) Treatment | Biotech Hunter | Biotech Hunter